dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Macarulla Mercadé, Teresa |
dc.contributor.author | Chen, Li-Tzong |
dc.contributor.author | Siveke, Jens T. |
dc.contributor.author | Bodoky, György |
dc.contributor.author | Li, Chung-Pin |
dc.contributor.author | Cunningham, David |
dc.date.accessioned | 2021-11-17T12:43:16Z |
dc.date.available | 2021-11-17T12:43:16Z |
dc.date.copyright | 2019 |
dc.date.issued | 2020-01 |
dc.identifier.citation | Macarulla Mercadé T, Chen LT, Li CP, Siveke JT, Cunningham D, Bodoky G, et al. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial. Pancreas. 2020 Jan;49(1):62–75. |
dc.identifier.issn | 1536-4828 |
dc.identifier.uri | https://hdl.handle.net/11351/6557 |
dc.description | Càncer de pàncrees metastàtic; Tractament previ; Irinotecan |
dc.description.sponsorship | The NAPOLI-1 study (ClinicalTrials.gov identifier: NCT01494506) was sponsored by Merrimack Pharmaceuticals, Inc, Cambridge, MA. |
dc.language.iso | eng |
dc.publisher | Wolters Kluwer Health |
dc.relation.ispartofseries | Pancreas;49(1) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Pàncrees - Càncer - Tractament |
dc.subject | Pàncrees - Càncer - Prognosi |
dc.subject.mesh | Pancreatic Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Treatment Outcome |
dc.title | Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1097/MPA.0000000000001455 |
dc.subject.decs | neoplasias pancreáticas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1097/MPA.0000000000001455 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Macarulla Mercadé T] Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Chen LT] National Institute of Cancer Research, National Health Research Institutes. Department of Internal Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan. [Li CP] Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital. National Yang-Ming University School of Medicine, Taipei, Taiwan. [Siveke JT] Division of Solid Tumor Translational Oncology, West German Cancer Center, University Hospital Essen. German Cancer Consortium (DKTK, partner site Essen) and German Cancer Research Center, DKFZ, Heidelberg, Germany. [Cunningham D] The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom. [Bodoky G] Department of Oncology, Szent László Hospital, Budapest, Hungary |
dc.identifier.pmid | 31856081 |
dc.identifier.wos | 000503790800006 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |